Genfit S.A. is a French biopharmaceutical company that focuses on discovering and developing drug candidates and diagnostic solutions for metabolic and liver-related diseases. Its current products in development include Elafibranor for primary biliary cholangitis, NIS4 technology for diagnosis of nonalcoholic steatohepatitis, GNS561 for cholangiocarcinoma, and Nitazoxanide for acute-on-chronic liver failure. Genfit also has licensing agreements with Labcorp and Genoscience Pharma.